Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
| Autor: | M.C. Post, M.C.J. van Thor, L. ten Klooster, Johannes J. Mager, Repke J. Snijder |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
Survival HR hazards regression mPAP mean pulmonary arterial pressure Chronic thromboembolic pulmonary hypertension i.e. id est 030204 cardiovascular system & hematology NT-proBNP N-terminal pro brain natriuretic peptide 0302 clinical medicine 030212 general & internal medicine CTEPH chronic thromboembolic pulmonary hypertension Clinical outcome FC functional class Cardiology RAP right atrial pressure PAH pulmonary arterial hypertension PAP pulmonary arterial pressure Cardiology and Cardiovascular Medicine AE adverse event medicine.drug medicine.medical_specialty BPA balloon pulmonary angioplasty PEA pulmonary endarterectomy CO cardiac output PH pulmonary hypertension Residual PH persistent pulmonary hypertension after PEA Pro-Brain Natriuretic Peptide PVR pulmonary vascular resistance Riociguat WHO World Health Organization 03 medical and health sciences Walking distance Internal medicine e.g. exempli gratiā medicine Effective treatment In patient Original Paper 6MWD 6-minute walking distance business.industry CHEST Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial Mean age lcsh:RC666-701 CW clinical worsening Clinical value sGC soluble guanylate cyclase business SD standard deviation ERA endothelin receptor antagonist Clinical worsening |
| Zdroj: | International Journal of Cardiology: Heart & Vasculature, Vol 22, Iss, Pp 163-168 (2019) International Journal of Cardiology. Heart & Vasculature IJC Heart and Vasculature, 22, 163 |
| ISSN: | 2352-9067 |
| Popis: | Background: To improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat. The aim of this study is to explore long-term outcomes and to compare our ‘real world’ data with previous research. Methods: We included all consecutive patients with technical inoperable and residual CTEPH, in whom riociguat therapy was initiated from January 2014 onwards, with patients followed till January 2019. Survival, clinical worsening (CW), functional class (FC), N-terminal pro brain natriuretic peptide (NT-proBNP) and 6-minute walking distance (6MWD) were described yearly after riociguat initiation. Results: Thirty-six patients (50% female, mean age 64.9 ± 12.1 years, 54% WHO FC III/IV and 6MWD 337 ± 138 m could be included, with a mean follow-up of 2.3 ± 1.2 years. Survival and CW-free survival three years after initiation of riociguat were 94% and 78%, respectively. The 6MWD per 10 m at baseline was a significant predictor (HR 0.90 [0.83–0.97], p = 0.009) for CW. At three years follow-up the WHO FC and 6MWD improved and NT-proBNP decreased compared to baseline. Conclusion: Our study confirms that riociguat is an effective treatment in patients with technical inoperable and residual CTEPH at long-term follow-up. Although our results are consistent with previous studies, more ‘real world’ research is necessary to confirm long-term results. Keywords: Chronic thromboembolic pulmonary hypertension, Riociguat, Clinical outcome, Survival, Clinical worsening |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|